Risk stratification and clinical outcomes in patients with acute pulmonary embolism

Clin Biochem. 2011 Sep;44(13):1110-1115. doi: 10.1016/j.clinbiochem.2011.06.077. Epub 2011 Jun 24.

Abstract

Objectives: Pulmonary embolism is a common disease associated with a high mortality rate. The risk assessment and appropriate treatment selection of patients with acute pulmonary embolism remains a challenge.

Design and methods: This single center cohort study included a total of 150 patients (96 male, age = 71 ± 15 years) with acute pulmonary embolism confirmed by spiral-computed tomography or magnetic resonance image. The prognostic performance of the clinical characteristics and laboratory values were investigated to predict the in-hospital hemodynamically instable events and 30-day all-cause mortality.

Results: The rate of in-hospital hemodynamic instability and 30-day all-cause mortality was 21% and 12%, respectively. A multivariate Cox regression analysis demonstrated that a heart rate ≥ 110 bpm (odd ratio 4.26 [95% CI 1.42-12.77]), chronic pulmonary disease (6.47 [1.99-21.04]), WBC ≥ 11,000 mm(3) (3.78 [1.32-10.82]), and D-dimer level ≥ 4.0 μg/mL (3.68 [1.01-13.43]) independently predicted the 30-day fatal outcome. A Kaplan-Meier survival analysis showed that the categorization based on the number of risk factors was significantly associated with the likelihood of 30-day all-cause mortality (P<0.0001).

Conclusions: The initial presentation of tachycardia, presence of chronic pulmonary disease, elevated WBC and D-dimer on admission can be used to identify the risk for a short-term fatal outcome within 30 days in patients with acute pulmonary embolism.

MeSH terms

  • Acute Disease
  • Aged
  • Aged, 80 and over
  • Cause of Death
  • Female
  • Fibrin Fibrinogen Degradation Products
  • Humans
  • Leukocyte Count
  • Lung Diseases
  • Male
  • Middle Aged
  • Prognosis
  • Pulmonary Embolism / diagnosis*
  • Pulmonary Embolism / mortality
  • Risk Assessment
  • Risk Factors
  • Survival Analysis
  • Tachycardia
  • Treatment Outcome

Substances

  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D